4/19
11:19 am
gthx
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit [Yahoo! Finance]
Low
Report
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Shift From Loss To Profit [Yahoo! Finance]
4/17
09:00 am
gthx
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
Low
Report
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
4/12
08:01 am
gthx
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Low
Report
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
4/4
10:34 am
gthx
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
Low
Report
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
4/4
10:30 am
gthx
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4/1
04:20 pm
gthx
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/22
05:56 pm
gthx
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape [Seeking Alpha]
Medium
Report
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape [Seeking Alpha]
3/1
04:20 pm
gthx
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/29
10:38 am
gthx
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/28
05:12 pm
gthx
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock, up previously from $4.00.
Low
Report
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock, up previously from $4.00.
2/28
12:14 pm
gthx
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Medium
Report
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
2/28
07:10 am
gthx
G1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023 [Yahoo! Finance]
High
Report
G1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023 [Yahoo! Finance]
2/28
06:38 am
gthx
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights [Yahoo! Finance]
High
Report
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights [Yahoo! Finance]
2/28
06:30 am
gthx
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
High
Report
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
2/27
08:43 am
gthx
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference [Yahoo! Finance]
Low
Report
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference [Yahoo! Finance]
2/27
08:30 am
gthx
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
Medium
Report
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
2/19
04:50 am
gthx
Small Cell Lung Cancer Therapeutics Market Forecast to Reach $10.87 Billion by 2028 Amid Advances in Early Detection and Treatment [Yahoo! Finance]
Medium
Report
Small Cell Lung Cancer Therapeutics Market Forecast to Reach $10.87 Billion by 2028 Amid Advances in Early Detection and Treatment [Yahoo! Finance]
2/17
09:06 am
gthx
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 47% loss last week hit both individual investors who own 60% as well as institutions [Yahoo! Finance]
Medium
Report
G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 47% loss last week hit both individual investors who own 60% as well as institutions [Yahoo! Finance]
2/15
08:30 am
gthx
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
Neutral
Report
G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024
2/13
08:40 am
gthx
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its price target lowered by analysts at Wedbush from $5.00 to $4.00. They now have an "outperform" rating on the stock.
High
Report
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its price target lowered by analysts at Wedbush from $5.00 to $4.00. They now have an "outperform" rating on the stock.
2/13
08:03 am
gthx
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its price target lowered by analysts at Needham & Company LLC from $14.00 to $12.00. They now have a "buy" rating on the stock.
High
Report
G1 Therapeutics, Inc. (NASDAQ: GTHX) had its price target lowered by analysts at Needham & Company LLC from $14.00 to $12.00. They now have a "buy" rating on the stock.
2/12
05:17 pm
gthx
G1 Therapeutics stock dives 36% post-market on P3 study update [Seeking Alpha]
High
Report
G1 Therapeutics stock dives 36% post-market on P3 study update [Seeking Alpha]
2/12
04:59 pm
gthx
CDNS, TRIP and SWAV are among after hour movers [Seeking Alpha]
High
Report
CDNS, TRIP and SWAV are among after hour movers [Seeking Alpha]
2/12
04:15 pm
gthx
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee [Yahoo! Finance]
High
Report
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee [Yahoo! Finance]
2/12
04:05 pm
gthx
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
High
Report
G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee